Actively Recruiting
Evaluation of 68GaGa-HBED-CC-PEG6-Exendin-4 Compared to 68GaGa-HBED-CC-Exendin-4 PETCT for Detecting Insulinoma in Adults
Led by Peking Union Medical College Hospital · Updated on 2026-09-09
20
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new PETCT imaging agent called 68GaGa-HBED-CC-PEG6-exendin-4 to locate insulinoma, a rare pancreatic tumor that causes severe low blood sugar. Insulinomas are often small and difficult to detect with standard imaging methods. This trial compares the new PEG6-modified tracer with an original similar tracer to see which better identifies insulinoma using PETCT scans. Participants will receive two PETCT scans within one week one with the new PEG6-modified tracer and one with the original tracer. The first three participants will also undergo dynamic PET scanning to study how the tracer behaves in the body and estimate radiation dose. After imaging, patients will have surgery or biopsy within 30 days to confirm tumor presence by pathology. During the trial, researchers collect medical history, lab tests, and prior imaging data before tracer injection. Two nuclear medicine physicians will analyze the scans without knowing which tracer was used to compare diagnostic accuracy. Participants are monitored for side effects from the injections and may withdraw anytime without penalty. All imaging costs are covered, and participants receive formal imaging reports for clinical use.
CONDITIONS
Brief Title
Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization
Research Team
Y
Yaping Luo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here